PC-SOD（Lecithinized Superoxide Dismutase）
Lecithinized Superoxide Dismutase and Medicine containing thereof（Japanese Patent No.3857338）
Lecithinized Superoxide Dismutase(PC-SOD) is a derivative of Superoxide Dismutase (SOD) linked with Lecithin moiety. PC-SOD is significantly superior to any modified SOD in metabolizing and cell affinity, so that PC-SOD possesses strong activity.
Drug composition containing Lecithinized Superoxide Dismutase （Japanese Patent No.3792487号）
Drug composition comprising PC-SOD and sucrose has been stabilized against degradation in long term storage (high stability), and has a good appearance after lyophilization.
Lecithinized Superoxide Dismutase Composition and process for producing the same（WO2006/040980）
The PC-SOD composition comprises PC-SOD’s which are obtained by replacing one or more of the amino groups of specific SOD with a lecithin moiety.
Therapeutic agent for Interstitial Pneumonia（WO2008/075706）
Therapeutic agent containing PC-SOD for idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis and drug inducing interstitial pneumonia.
Inhalant comprising modified Superoxide Dismutase (WO2010/064522）
Inhalant comprising PC-SOD.
Amelioration agent for Chronic Obstructive Pulmonary Disease（WO2010/103959）
Amelioration agent containing PC-SOD for Chronic Obstructive Pulmonary Disease (COPD).
AS-013
Therapeutic agent for ameliorating prognosis after lower limb amputation surgery（WO2008/105260）
Therapeutic agent containing Prostaglandin E1 derivative (AS-013）for ameliorating prognosis after lower limb amputation surgery induced by severe peripheral arterial disease.
Nanoparticle
Nanoparticle containing water-soluble non-peptidic low molecular weight substance (WO2007/074604)
Nanoparticle containing non-peptidic drug which is excellent in targeting to affected part and sustained release of the drug and shows a reduced accumulation of the drug in the liver. The nanoparticle can be prepared by hydrophobizing a drug with a metal ion and reacting with a polylactic acid – polyethylene glycol block copolymer and lactic acid.
Low molecule drug containing nanoparticle having sustained release negatively charged group（WO2008/139804）
In case of above nanoparticle ①, L- lactic acid can be used instead of DL- lactic acid. The nanoparticle has excellent drug sustained release properties.
Nanoparticle containing low molecule drug（Filed in PCT）
Nanoparticle containing low molecule drug is reduced phenomenon of Accelerated Blood Clearance (ABC phenomenon), and can be prepared using polylactic acid – polyvinylpyrrolidone block copolymer.
Nanoparticle containing ProstaglandinＩ2 derivative （Filed in JPO）
Nanoparticle containing Beraprost sodium is superior to Beraprost sodium in drug sustaining and accumulation in blood.
Others
Novel Prostaglandin E1 derivative and nanoparticle encapsulated the same （WO2010/058669）
Prostaglandin E1 derivative is a compound having terminal carboxyl group linked with phosphoric-alkylene group, and nanoparticle encapsulated the same shows excellent slow drug release property and effective targeting.
Loxoprofen derivative and pharmaceutical containing the same（WO2010/098251）
Loxoprofen derivative avoids side effects such as gastrointestinal disorders, and has excellent anti-inflammatory and analgesic effects.
Agent inducing differentiation of cancer stem cell（Filed in JPO）
Hair restoration agent（Filed in JPO）
In order to view the PDF files, you will need to download the Acrobat Reader.
